RNA Biomarkers As a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the added value of early RNA biomarkers on predicting progression-free survival (PFS) and overall survival (OS) were explored. The RNA biomarkers: mRNA, miR-375, miR-3687, and were measured in 93 patients with mCRPC, before and 1 month after start of first-line abiraterone acetate or enzalutamide treatment, in two prospective clinical trials. The added value of the biomarkers to standard clinical parameters in predicting PFS and OS was tested by Harell's C-index. To test whether the biomarkers were independent markers of PFS and OS, multivariate Cox regression was used. The best prediction model for PFS and OS was formed by adding miR-375 and (at baseline and 1 month) to standard clinical parameters. Baseline miR-375 and detectable after 1 month of therapy were independently related to shorter PFS, which was not observed for OS. In conclusion, the addition of and miR-375 (at baseline and 1 month) to standard clinical parameters resulted in the best prediction model for survival assessment.